Helen of Troy
This article was originally published in The Rose Sheet
Executive Summary
Fiscal 2004 third quarter net sales advanced 25.3% to $179.2 mil. with growth in all business segments except Tactica, Helen of Troy reports Jan. 14. Idelle Labs, which includes the Sea Breeze, Final Net, 3-in-1 brands acquired from P&G in 2002, as well as Brut cologne purchased from Unilever in September, accounted for roughly 30% of growth, or $12.3 mil., in Q3 (ended Nov. 30). Revenues for the Tactica depilatory business fell about 27% during the period to $13.8 mil. due to softness in the infomercial channel and a decline in Epil Stop sales. Helen of Troy recently announced it is "evaluating strategic alternatives" for Tactica (1"The Rose Sheet" Oct. 6, 2003, p. 7). Net income during the period rose 49.3% to $25.1 mil. The company also raised its fiscal year earnings per diluted share guidance from $1.85-$1.90 to $2.05-$2.10...
You may also be interested in...
Helen Of Troy Exploring Options For Tactica Depilatory Business
Helen of Troy is "evaluating strategic alternatives" for its investment in Tactica, the firm's depilatory products business, Chairman, President and CEO Gerald Rubin announced during a second quarter sales and earnings presentation Oct. 2
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.